TG Therapeutics | TGTX - Gross Profit On Sales


TG Therapeutics reported $171.41M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
AbbVie USD 12.54B 474M Mar/2026
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Amgen USD 6.89B 415M Dec/2025
Ardelyx USD 114.37M 8.02M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bayer EUR 6.94B 1.58B Dec/2025
Biogen USD 1.82B 169.5M Mar/2026
Corcept Therapeutics USD 162.02M 37.56M Mar/2026
Curis USD 1.14M 8.86M Dec/2025
Gilead Sciences USD 5.52B 791M Mar/2026
Infinity Pharmaceuticals USD 231K 59K Jun/2023
J&J USD 17.24B 642M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Novavax USD 125.04M 76.09M Dec/2025
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
TG Therapeutics USD 171.41M 16.98M Mar/2026
Verastem USD 14.64M 14.1M Dec/2025
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026